Clinical Trials

CompassHER2 RD

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

DESTINY-Breast01

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

DESTINY-Gastric01

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

DESTINY-Gastric04

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

DESTINY-Lung01

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer (DESTINY-Lung01)

DESTINY-Lung02

Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)

HER2CLIMB

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer (HER2CLIMB)

HER2CLIMB-02

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

HER2CLIMB-04

A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer (HER2CLIMB-04)

MAHOGANY

Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY)

MOUNTAINEER-02

Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (MOUNTAINEER-02)

SOPHIA

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (SOPHIA)

Clinical Trials

CompassHER2 RD

DESTINY-Breast01

DESTINY-Gastric01

DESTINY-Gastric04

DESTINY-Lung01

DESTINY-Lung02

HER2CLIMB

HER2CLIMB-02

HER2CLIMB-04

MAHOGANY

MOUNTAINEER-02

SOPHIA

Guidelines

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®): Breast Cancer

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®): Non-Small Cell Lung Cancer

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®): Gastric Cancer

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®): Esophageal and Esophagogastric Cancers

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®): Colon Cancer

Package Inserts

Margetuximab

Trastuzumab deruxtecan

Tucatinib

Overcoming Disease Recurrence and Treatment Resistance in HER2-Positive Metastatic Tumors – Resource Center